Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers
release_a6kzna7kmzgjhpsfubgeavdmmu
by
Nicholas J. Ashton, Marc Suárez-Calvet, Amanda Heslegrave, Abdul Hye, Cristina Razquin, Pau Pastor, Raquel Sanchez-Valle, José L. Molinuevo, Pieter Jelle Visser, Kaj Blennow, Angela K. Hodges, Henrik Zetterberg
2019 Volume 11, Issue 1, p94
Abstract
Results from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer's disease (AD) can be replicated in blood, e.g. amyloid-beta peptides (Aβ42 and Aβ40) and neurofilament light chain (NFL). Such data proposes that blood is a rich source of potential biomarkers reflecting central nervous system pathophysiology and should be fully explored for biomarkers that show promise in CSF. Recently, soluble fragments of the triggering receptor expressed on myeloid cells 2 (sTREM2) protein in CSF have been reported to be increased in prodromal AD and also in individuals with TREM2 rare genetic variants that increase the likelihood of developing dementia.
In text/plain
format
Archived Files and Locations
application/pdf 703.2 kB
file_m734t6l37zc3bnjymh445g3h6u
|
alzres.biomedcentral.com (web) web.archive.org (webarchive) |
application/pdf 748.4 kB
file_mqc5tnfn6zfjlfid45gxzcxixm
|
kclpure.kcl.ac.uk (web) web.archive.org (webarchive) |
access all versions, variants, and formats of this works (eg, pre-prints)
Crossref Metadata (via API)
Worldcat
SHERPA/RoMEO (journal policies)
wikidata.org
CORE.ac.uk
Semantic Scholar
Google Scholar